April 3, 2017

IM HealthScience® (IMH) today announced favorable results from its Functional Dyspepsia Safety Update at 6 months (FDSU-6), a real-world, post-marketing surveillance study reporting on the safety and tolerability profile of FDgard® among an estimated 182,638 patients who used the product. The results found no serious adverse events.

Read More

May 12, 2016

IM HealthScience® (IMH) today announced the nationwide availability of FDgard™, a new medical food specially formulated for the dietary management of Functional Dyspepsia..

Read More

May 23, 2016

IM HealthScience® (IMH), innovators of non- prescription IBgard® for the management of irritable bowel syndrome (IBS), announced today the planned retirement of Ellen Geisel...

Read More

October 17, 2016

(IMH) today announced interim results of FDACT™ (Functional Dyspepsia Adherence and Compliance Trial), a real-world observational study of 205 patients who took FDgard®...

Read More